← Back to Search

Ganaxolone for Epilepsy

Phase 2
Waitlist Available
Research Sponsored by Marinus Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of the double-blind 17 week treatment period
Awards & highlights

Summary

This trial is testing ganaxolone, a medication that may help reduce seizures, in female children and young adults with a specific genetic mutation (PCDH19). The study will evaluate if ganaxolone is effective and safe. Ganaxolone works by balancing brain signals to make seizures less likely. Ganaxolone, a synthetic neuroactive steroid, is approved by the US Food and Drug Administration (FDA) to treat seizures in patients with CDKL5 deficiency disorder.

Eligible Conditions
  • Epilepsy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~end of the double-blind 17 week treatment period
This trial's timeline: 3 weeks for screening, Varies for treatment, and end of the double-blind 17 week treatment period for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Summary of 28-day Seizure Frequency Through 17 Week Post-Baseline Phase (Median Percent Change)
Secondary study objectives
50% Primary Seizure Reduction
Summary of 28-day Seizure Frequency for Subjects in the Biomarker-positive Stratum (Median Percent Change)

Side effects data

From 2014 Phase 2 trial • 112 Patients • NCT01339689
19%
Somnolence
14%
Headache
8%
Fatigue
8%
Sedation
7%
Dizziness
7%
Nightmare
7%
Vision blurred
7%
Myalgia
5%
Confusional state
5%
Dysarthria
3%
Vertigo
3%
Gastrointestinal disorder
3%
Pain in extremity
3%
Tremor
3%
Neck pain
3%
Nasopharyngitis
3%
Increased appetite
3%
Ataxia
3%
Balance disorder
3%
Cough
3%
Insomnia
3%
Diarrhoea
3%
Lethargy
2%
Dry mouth
2%
Confusion
2%
Pulmonary congestion
2%
Upper respiratory tract infection
2%
Rhinorrhoea
2%
Splenomegaly
2%
Urinary tract infection
2%
Road traffic accident
2%
Arthralgia
2%
Balance Issues
2%
Protein urine present
2%
Tandem galt test abnormal
2%
Vomiting
2%
Chest pain
2%
Decreased appetite
2%
Abnormal dreams
2%
Nausea
2%
Chest discomfort
2%
Feeling drunk
2%
Irritability
2%
Pharyngitis streptococcal
2%
Blood urine present
2%
Weight increased
2%
Back pain
2%
Muscle spasms
2%
Depressed level of consciousness
2%
Disturbance in attention
2%
Motor dysfunction
2%
Anger
2%
Depressed
2%
Euphoric mood
2%
Initial insomnia
2%
Psychomotor retardation
2%
Sleep disorder
2%
Upper airway resistance syndrome
2%
Anorgasmia
2%
Suicidal ideation
2%
Haematuria
2%
Suicide of companion
2%
Product used for unknown indication
2%
Dry Eye
2%
Abdominal discomfort
2%
Alanine aminotransferase increased
2%
Liver function test abnormal
2%
Tic
2%
Migraine
2%
Suicidal Ideation
2%
Fever
2%
Sinus congestion
2%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ganaxolone
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: GanaxoloneExperimental Treatment1 Intervention
ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
Group II: PlaceboPlacebo Group1 Intervention
placebo suspension 3x's /day for 17 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ganaxolone
FDA approved

Find a Location

Who is running the clinical trial?

Marinus PharmaceuticalsLead Sponsor
22 Previous Clinical Trials
1,744 Total Patients Enrolled
6 Trials studying Epilepsy
577 Patients Enrolled for Epilepsy
Maciej Gasior, M.D., Ph.DStudy DirectorMarinus Pharmaceuticals, Inc.
Paula Bokesk, M.D., FAAPStudy DirectorMarinus Pharmaceuticals, Inc.
~5 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top